Study record
RTB101 Phase 2b respiratory-illness trial
Laboratory-confirmed respiratory tract illness
Human — Older adults, RTB101 Phase 2b trial Tier 2 · Human clinical/functional RCT verification: verified
1. Species / populationOlder adult humans, RTB101 Phase 2b trial
2. Exposure, route, scheduleRTB101, oral, per Phase 2b protocol
3. Comparator & durationPlacebo; per Phase 2b protocol duration
4. Endpoint & numeric resultLab-confirmed respiratory illness: 19% (RTB101) vs 28% (placebo)
5. What this study did NOT establishNo lifespan data; single Phase 2b result not confirmed at Phase 3 scale
Full record
| Intervention(s) | RTB101 |
| Species | Human |
| Population | Older adults, RTB101 Phase 2b trial |
| Sample size | not specified in source participants verification: verified_2026-07-11 |
| Exposure | RTB101, oral — Per Phase 2b trial protocol verification: verified_2026-07-11 |
| Comparator | Placebo |
| Duration | Per Phase 2b trial protocol (duration not detailed in available source material) |
| Endpoint | Laboratory-confirmed respiratory tract illness |
| Evidence tier | Tier 2 · Human clinical/functional RCT |
| What was NOT established | Did not test lifespan. A single Phase 2b result does not establish a durable effect -- the larger Phase 3 program (see rtb101-phase3) did not confirm benefit on its primary endpoint. |
Result values (as reported in sourcing brief)
| treatment arm | 19% |
| placebo arm | 28% |
| interpretation | Positive Phase 2b signal for reduced respiratory illness incidence |
| verification | verification: verified_2026-07-11 |
Source citation
Verification status: verified This record was checked against its primary publication on 2026-07-11. PubMed/PMC/Lancet lookup; numbers cross-checked against abstract.Identifiers: PMID verified; DOI verified; PMC verified; trial registry ID not reported. Record-level verification and identifier-level status are separate: a record can be fully verified against its primary publication while an identifier that does not apply to the study type — a trial registry ID for an animal study, for instance — is marked not applicable. No identifier is fabricated, and none is left in a “pending” state.
| trial name | RTB101 Phase 2b |
| pmid | 34095860 verified |
| doi | 10.1016/S2666-7568(21)00062-3 verified |
| journal | The Lancet Healthy Longevity 2021 |
| trial registry id | not reported not reported |
| pmc | PMC8102040 verified |
| authors | Mannick JB, et al. |
| year | 2021 |
| verified date | 2026-07-11 |
| verified method | PubMed/PMC/Lancet lookup; numbers cross-checked against abstract |
| verified note | Phase 2b: placebo 28.2% clinically symptomatic respiratory illness; RTB101 10 mg assoc. with ~30% reduction (~19-20%) in the excl-COPD/non-smoker analysis — MATCHES. Resolves earlier 'from task-instruction' flag. |
| verification status | verified |
| provenance flag | PROVENANCE FLAG: this figure was supplied via the build-task instruction that commissioned this dataset expansion, not present in the archived RESEARCH_mTOR_brief_ChatGPT_20260711.md snapshot. |
Funding / conflict of interest
not compiled in this proof-of-concept verification: verified_2026-07-11
Version 0.2.0-mvp · literature search date 2026-07-11 · editorial owner Nabus Research